Global gastric cancer therapeutics market is anticipated to show a robust growth in the upcoming five years, 2023-2027. The market is expected to show an impressive growth of CAGR in the forecast period owing to the rising cases of cancer and limited number of effective drugs. Moreover, the research and development that is consistently being conducted by various research institutes and labs is expected to drive the growth of global gastric cancer therapeutics market in the next five years.
Also, the growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, etc. are also driving the growth of the global gastric cancer therapeutics market. Treatment for gastric cancer basically depends upon the stage of cancer. Various treatment methods are found at such as surgery, targeted drugs, chemotherapy, etc. The factors that propel the growth of the global gastric cancer therapeutics market include innovations in treatment, a growing number of cancer treatment centers, increasing research and development activities, and combination therapies.
The global gastric cancer therapeutics market is segmented on the basis of therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitive landscape, and regional distribution. Based on therapy type the market is further bifurcated into Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery.
Targeted therapy is anticipated to hold the largest share of the market in the forecast period. The growth can be attributed to the delivery of advanced technological approaches like stem cell therapy, etc. Chemotherapy is also anticipated to hold the significant amount of market share owing to its efficiency in controlling the growth of the cancerous cells and thus have proved to be quite beneficial.
Some of the major competitors in the market are Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc., among others.
Objective of the Study
- To analyze the historical growth of the market size of global gastric cancer therapeutics market from 2017 to 2021.
- To estimate and forecast the market size of global gastric cancer therapeutics market from 2022 to 2027 and growth rate until 2027.
- To classify and forecast global gastric cancer therapeutics market based on therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitional landscape, and regional distribution.
- To identify dominant region or segment in the global gastric cancer therapeutics market.
- To identify drivers and challenges for global gastric cancer therapeutics market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global gastric cancer therapeutics market.
- To identify and analyze the profile of leading players operating in global gastric cancer therapeutics market.
- To identify key sustainable strategies adopted by market players in global gastric cancer therapeutics market.
Click here to download the sample
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the globe.
TechSci Research calculated the market size of global gastric cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience
- Manufacturers, end users, service providers and other stakeholders
- Distributers and suppliers of gastric cancer therapeutics and other stakeholders
- Organizations, forums, and alliances related to gastric cancer therapeutics market
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as vendors, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
| Attribute | Details |
| Base Year | 2021 |
| Historical Years | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million and CAGR for 2017-2021 and 2022-2027 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | - Therapy Type
- Disease Indication
- Molecule Type
- Line of Therapy
- Mode of Action
- Route of Administration
- End User
- Distribution Channel
|
| Regional Scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
| Country Scope | United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa; |
| Key Companies Profiled | Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc.. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
